LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 104

Search options

  1. Article ; Online: Pathophysiology of Hepatorenal Syndrome.

    Velez, Juan Carlos Q / Latt, Nyan / Rodby, Roger A

    Advances in kidney disease and health

    2024  Volume 31, Issue 2, Page(s) 87–99

    Abstract: Hepatorenal syndrome type 1 (HRS-1) is a unique form of acute kidney injury that affects individuals with decompensated cirrhosis with ascites. The primary mechanism leading to reduction of kidney function in HRS-1 is hemodynamic in nature. Cumulative ... ...

    Abstract Hepatorenal syndrome type 1 (HRS-1) is a unique form of acute kidney injury that affects individuals with decompensated cirrhosis with ascites. The primary mechanism leading to reduction of kidney function in HRS-1 is hemodynamic in nature. Cumulative evidence points to a cascade of events that led to a profound reduction in kidney perfusion. A state of increased intrahepatic vascular resistance characteristic of advanced cirrhosis and portal hypertension is accompanied by maladaptive peripheral arterial vasodilation and reduction in systemic vascular resistance and mean arterial pressure. As a result of a fall in effective arterial blood volume, there is a compensatory activation of the sympathetic nervous system and the renin-angiotensin system, local renal vasoconstriction, loss of renal autoregulation, decrease in renal blood flow, and ultimately a fall in glomerular filtration rate. Systemic release of nitric oxide stimulated by the fibrotic liver, bacterial translocation, and inflammation constitute key components of the pathogenesis. While angiotensin II and noradrenaline remain the critical mediators of renal arterial and arteriolar vasoconstriction, other novel molecules have been recently implicated. Although the above-described mechanistic pathway remains the backbone of the pathogenesis of HRS-1, other noxious elements may be present in advanced cirrhosis and likely contribute to the renal impairment. Direct liver-kidney crosstalk via the hepatorenal sympathetic reflex can further reduce renal blood flow independently of the systemic derangements. Tense ascites may lead to intraabdominal hypertension and abdominal compartment syndrome. Cardio-hemodynamic processes have also been increasingly recognized. Porto-pulmonary hypertension, cirrhotic cardiomyopathy, and abdominal compartment syndrome may lead to renal congestion and complicate the course of HRS-1. In addition, a degree of ischemic or toxic (cholemic) tubular injury may overlap with the underlying circulatory dysfunction and further exacerbate the course of acute kidney injury. Improving our understanding of the pathogenesis of HRS-1 may lead to improvements in therapeutic options for this seriously ill population.
    MeSH term(s) Humans ; Hepatorenal Syndrome/physiopathology ; Hepatorenal Syndrome/therapy ; Hepatorenal Syndrome/etiology ; Liver Cirrhosis/physiopathology ; Liver Cirrhosis/complications ; Renal Circulation/physiology ; Hemodynamics/physiology ; Renin-Angiotensin System/physiology ; Kidney/physiopathology ; Hypertension, Portal/physiopathology ; Ascites/physiopathology
    Language English
    Publishing date 2024-04-22
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 3156601-7
    ISSN 2949-8139
    ISSN (online) 2949-8139
    DOI 10.1053/j.akdh.2024.01.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Hepatorenal Syndrome Type 1: From Diagnosis Ascertainment to Goal-Oriented Pharmacologic Therapy.

    Velez, Juan Carlos Q

    Kidney360

    2021  Volume 3, Issue 2, Page(s) 382–395

    Abstract: Hepatorenal syndrome type 1 (HRS-1) is a serious form of AKI that affects individuals with advanced cirrhosis with ascites. Prompt and accurate diagnosis is essential for effective implementation of therapeutic measures that can favorably alter its ... ...

    Abstract Hepatorenal syndrome type 1 (HRS-1) is a serious form of AKI that affects individuals with advanced cirrhosis with ascites. Prompt and accurate diagnosis is essential for effective implementation of therapeutic measures that can favorably alter its clinical course. Despite decades of investigation, HRS-1 continues to be primarily a diagnosis of exclusion. Although the diagnostic criteria dictated by the International Club of Ascites provide a useful framework to approach the diagnosis of HRS-1, they do not fully reflect the complexity of clinical scenarios that is often encountered in patients with cirrhosis and AKI. Thus, diagnostic uncertainty is often faced. In particular, the distinction between HRS-1 and acute tubular injury is challenging with the currently available clinical tools. Because treatment of HRS-1 differs from that of acute tubular injury, distinguishing these two causes of AKI has direct implications in management. Therefore, the use of the International Club of Ascites criteria should be enhanced with a more individualized approach and attention to the other phenotypic aspects of HRS-1 and other types of AKI. Liver transplantation is the most effective treatment for HRS-1, but it is only available to a small fraction of the affected patients worldwide. Thus, pharmacologic therapy is necessary. Vasoconstrictors aimed to increase mean arterial pressure constitute the most effective approach. Administration of intravenous albumin is an established co-adjuvant therapy. However, the risk for fluid overload in patients with cirrhosis with AKI is not negligible, and interventions intended to expand or remove volume should be tailored to the specific needs of the patient. Norepinephrine and terlipressin are the most effective vasoconstrictors, and their use should be determined by availability, ease of administration, and attention to optimal risk-benefit balance for each clinical scenario.
    MeSH term(s) Acute Kidney Injury/diagnosis ; Goals ; Hepatorenal Syndrome/diagnosis ; Humans ; Liver Cirrhosis/complications ; Terlipressin/therapeutic use
    Chemical Substances Terlipressin (7Z5X49W53P)
    Language English
    Publishing date 2021-12-03
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 2641-7650
    ISSN (online) 2641-7650
    DOI 10.34067/KID.0006722021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Kidney Replacement Therapy in Patients with Acute Liver Failure and End-Stage Cirrhosis Awaiting Liver Transplantation.

    Kovvuru, Karthik / Velez, Juan Carlos Q

    Clinics in liver disease

    2022  Volume 26, Issue 2, Page(s) 245–253

    Abstract: Providing dialysis to patients with liver failure is challenging because of their tenuous hemodynamics and refractory ascites. With better machinery and increased availability, continuous kidney replacement therapy has been successfully delivered to ... ...

    Abstract Providing dialysis to patients with liver failure is challenging because of their tenuous hemodynamics and refractory ascites. With better machinery and increased availability, continuous kidney replacement therapy has been successfully delivered to acutely ill patients in liver failure over the past few decades. Intermittent hemodialysis continues to remain the modality of choice outside the intensive care unit and on occasion needs to be complemented with paracentesis. Peritoneal dialysis has not been widely used, but recent literature shows promising outcomes barring for publication bias. Albumin dialysis could be a lifesaving procedure for a carefully selected subgroup of patients with liver failure.
    MeSH term(s) Humans ; Liver Cirrhosis/complications ; Liver Failure/etiology ; Liver Failure, Acute/etiology ; Liver Failure, Acute/surgery ; Liver Transplantation/adverse effects ; Renal Replacement Therapy
    Language English
    Publishing date 2022-04-01
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1472315-3
    ISSN 1557-8224 ; 1089-3261
    ISSN (online) 1557-8224
    ISSN 1089-3261
    DOI 10.1016/j.cld.2022.01.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: The Kidney and Liver Disease Connection.

    Velez, Juan Carlos Q / Gudsoorkar, Prakash / Maddukuri, Geetha / Thakar, Charuhas

    Advances in kidney disease and health

    2024  Volume 31, Issue 2, Page(s) 85–86

    Language English
    Publishing date 2024-03-23
    Publishing country United States
    Document type Editorial
    ZDB-ID 3156601-7
    ISSN 2949-8139
    ISSN (online) 2949-8139
    DOI 10.1053/j.akdh.2024.02.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Patients with Hepatorenal Syndrome Should Be Dialyzed? PRO.

    Velez, Juan Carlos Q

    Kidney360

    2020  Volume 2, Issue 3, Page(s) 406–409

    MeSH term(s) Acute Kidney Injury ; Hepatorenal Syndrome/diagnosis ; Humans ; Liver Cirrhosis/complications
    Language English
    Publishing date 2020-12-16
    Publishing country United States
    Document type Journal Article ; Comment
    ISSN 2641-7650
    ISSN (online) 2641-7650
    DOI 10.34067/KID.0006952020
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Fever and Confusion in an Elderly Man with AKI.

    Kanduri, Swetha R / Carbajal, Nicholas / Velez, Juan Carlos Q

    Kidney360

    2023  Volume 4, Issue 10, Page(s) 1528–1529

    MeSH term(s) Male ; Humans ; Aged ; Confusion/etiology ; Fever ; Acute Kidney Injury/diagnosis ; Acute Kidney Injury/etiology
    Language English
    Publishing date 2023-10-26
    Publishing country United States
    Document type Journal Article
    ISSN 2641-7650
    ISSN (online) 2641-7650
    DOI 10.34067/KID.0000000000000193
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Entwined Fates: Decoding the Parallel yet Intersecting Pathways of Liver and Kidney Disease.

    Gudsoorkar, Prakash S / Maddukuri, Geetha / Velez, Juan Carlos Q

    Advances in kidney disease and health

    2023  Volume 30, Issue 4, Page(s) 305–306

    MeSH term(s) Humans ; Abdomen ; Liver ; Kidney Diseases/diagnosis
    Language English
    Publishing date 2023-09-01
    Publishing country United States
    Document type Editorial
    ZDB-ID 3156601-7
    ISSN 2949-8139
    ISSN (online) 2949-8139
    DOI 10.1053/j.akdh.2023.07.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Kidney Dysfunction in the Setting of Liver Failure: Core Curriculum 2024.

    Kanduri, Swetha R / Velez, Juan Carlos Q

    American journal of kidney diseases : the official journal of the National Kidney Foundation

    2023  Volume 83, Issue 3, Page(s) 386–401

    Abstract: Individuals with liver disease are susceptible to pathophysiological derangements that lead to kidney dysfunction. Patients with advanced cirrhosis and acute liver failure (ALF) are at risk of developing acute kidney injury (AKI). Hepatorenal syndrome ... ...

    Abstract Individuals with liver disease are susceptible to pathophysiological derangements that lead to kidney dysfunction. Patients with advanced cirrhosis and acute liver failure (ALF) are at risk of developing acute kidney injury (AKI). Hepatorenal syndrome type 1 (HRS-1, also called HRS-AKI) constitutes a form of AKI unique to the state of cirrhosis and portal hypertension. Although HRS-1 is a condition primarily characterized by marked renal vasoconstriction and kidney hypoperfusion, other pathogenic processes, such as acute tubular injury and renal vein congestion, can overlap and further complicate the course of HRS-1. ALF can lead to AKI through mechanisms that involve systemic inflammation, direct drug toxicity, or bile acid-induced tubulopathy. In addition, the growing prevalence of nonalcoholic steatohepatitis is changing the spectrum of chronic kidney disease in cirrhosis. In this installment of AJKD's Core Curriculum in Nephrology, we explore the underpinnings of how cirrhosis, ALF, acute cholestasis, and post-liver transplantation can be associated with various forms of acute, subacute, or chronic kidney diseases. We navigate through the recommended therapies for each condition, including supportive care, pharmacological interventions, kidney replacement therapy, and organ transplantation. Finally, key acid-base and electrolyte disorders associated with hepatobiliary disease are also summarized.
    MeSH term(s) Humans ; Kidney/pathology ; Liver Cirrhosis/complications ; Hepatorenal Syndrome/etiology ; Hepatorenal Syndrome/therapy ; Acute Kidney Injury/epidemiology ; Acute Kidney Injury/etiology ; Acute Kidney Injury/therapy ; Liver Failure/complications ; Liver Failure/pathology
    Language English
    Publishing date 2023-12-07
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 604539-x
    ISSN 1523-6838 ; 0272-6386
    ISSN (online) 1523-6838
    ISSN 0272-6386
    DOI 10.1053/j.ajkd.2023.08.013
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Acute Kidney Injury in Patients with Liver Disease.

    Cullaro, Giuseppe / Kanduri, Swetha Rani / Velez, Juan Carlos Q

    Clinical journal of the American Society of Nephrology : CJASN

    2022  Volume 17, Issue 11, Page(s) 1674–1684

    Abstract: AKI is commonly encountered in patients with decompensated cirrhosis, and it is associated with unfavorable outcomes. Among factors specific to cirrhosis, hepatorenal syndrome type 1, also referred to as hepatorenal syndrome-AKI, is the most salient and ... ...

    Abstract AKI is commonly encountered in patients with decompensated cirrhosis, and it is associated with unfavorable outcomes. Among factors specific to cirrhosis, hepatorenal syndrome type 1, also referred to as hepatorenal syndrome-AKI, is the most salient and unique etiology. Patients with cirrhosis are vulnerable to traditional causes of AKI, such as prerenal azotemia, acute tubular injury, and acute interstitial nephritis. In addition, other less common etiologies of AKI specifically related to chronic liver disease should be considered, including abdominal compartment syndrome, cardiorenal processes linked to cirrhotic cardiomyopathy and portopulmonary hypertension, and cholemic nephropathy. Furthermore, certain types of GN can cause AKI in cirrhosis, such as IgA nephropathy or viral hepatitis related. Therefore, a comprehensive diagnostic approach is needed to evaluate patients with cirrhosis presenting with AKI. Management should be tailored to the specific underlying etiology. Albumin-based volume resuscitation is recommended in prerenal AKI. Acute tubular injury and acute interstitial nephritis are managed with supportive care, withdrawal of the offending agent, and, potentially, corticosteroids in acute interstitial nephritis. Short of liver transplantation, vasoconstrictor therapy is the primary treatment for hepatorenal syndrome type 1. Timing of initiation of vasoconstrictors, the rise in mean arterial pressure, and the degree of cholestasis are among the factors that determine vasoconstrictor responsiveness. Large-volume paracentesis and diuretics are indicated to relieve intra-abdominal hypertension and renal vein congestion. Direct-acting antivirals with or without immunosuppression are used to treat hepatitis B/C-associated GN. In summary, AKI in cirrhosis requires careful consideration of multiple potentially pathogenic factors and the implementation of targeted therapeutic interventions.
    MeSH term(s) Humans ; Hepatorenal Syndrome/diagnosis ; Hepatorenal Syndrome/etiology ; Hepatorenal Syndrome/therapy ; Antiviral Agents/therapeutic use ; Biomarkers ; Hepatitis C, Chronic/complications ; Acute Kidney Injury/diagnosis ; Acute Kidney Injury/etiology ; Acute Kidney Injury/therapy ; Liver Cirrhosis/complications ; Liver Cirrhosis/diagnosis ; Vasoconstrictor Agents/therapeutic use ; Nephritis, Interstitial/drug therapy
    Chemical Substances Antiviral Agents ; Biomarkers ; Vasoconstrictor Agents
    Language English
    Publishing date 2022-07-28
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2226665-3
    ISSN 1555-905X ; 1555-9041
    ISSN (online) 1555-905X
    ISSN 1555-9041
    DOI 10.2215/CJN.03040322
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Hyponatremia in Cirrhosis.

    Rondon-Berrios, Helbert / Velez, Juan Carlos Q

    Clinics in liver disease

    2022  Volume 26, Issue 2, Page(s) 149–164

    Abstract: Hyponatremia is the most common electrolyte disorder encountered in clinical practice, and it is a common complication of cirrhosis reflecting an increase in nonosmotic secretion of arginine vasopressin as a result of of the circulatory dysfunction that ... ...

    Abstract Hyponatremia is the most common electrolyte disorder encountered in clinical practice, and it is a common complication of cirrhosis reflecting an increase in nonosmotic secretion of arginine vasopressin as a result of of the circulatory dysfunction that is characteristic of advanced liver disease. Hyponatremia in cirrhosis has been associated with poor clinical outcomes including increased risk of morbidity and mortality, poor quality of life, and heightened health care utilization. Despite this, the treatment of hyponatremia in cirrhosis remains challenging as conventional therapies such as fluid restriction are frequently ineffective. In this review, we discuss the epidemiology, clinical outcomes, pathogenesis, etiology, evaluation, and management of hyponatremia in cirrhosis.
    MeSH term(s) Humans ; Hyponatremia/epidemiology ; Hyponatremia/etiology ; Hyponatremia/therapy ; Liver Cirrhosis ; Quality of Life
    Language English
    Publishing date 2022-04-01
    Publishing country United States
    Document type Journal Article ; Review ; Research Support, N.I.H., Extramural
    ZDB-ID 1472315-3
    ISSN 1557-8224 ; 1089-3261
    ISSN (online) 1557-8224
    ISSN 1089-3261
    DOI 10.1016/j.cld.2022.01.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top